FRIPRO-Fri prosjektstøtte

High-dimensional analysis of AXL-mediated immunotherapy resistance: Clinical translation for personalized medicine

Kreft er nå den ledende dødsårsak i Norge. Selv om nye medisiner som aktiverer kroppens immunsystem (immunoterapi) har forbedret vår evne til å behandle kreft, får ikke de fleste pasienter vedvarende behandlingseffekt. De fleste krefttyper blir resistent mot terapi, sprer seg i kroppen og underg...

Tildelt: kr 12,0 mill.

Prosjektperiode: 2020-2026

Sted: Vestland

FRIMEDBIO-Fri prosj.st. med.,helse,biol

Axl regulates stem cell traits in normal and malignant epithelial cells: Basic biology and clinical translation

Nye medisiner har bedret vårt evne til å behandle kreft, men fortsatt blir de fleste kreftpasienter resistent mot terapi og kreft er fortsatt en ledende dødsårsak. Derfor er det viktig å forstå hvordan kreftceller blir motstandsdyktige. Kreftceller kan reaktiverer genprogrammer som gir dem stamce...

Tildelt: kr 8,8 mill.

Prosjektperiode: 2015-2018

Sted: Vestland

IS-BILAT-Mobilitet Norge-USA /Canada

New experimental approaches to study normal and cancer stem cells

As part of an approved sabbatical September 1, 2011 - September 1, 2012 I will conduct research at Lawrence Berkeley National Laboratory (LBNL) and Stanford University in the San Francisco Bay Area to build expertise in stem cell biology and state-of-the- art high content screening technologies. ...

Tildelt: kr 0,32 mill.

Prosjektperiode: 2011-2011

Sted: Vestland

FRIMEDBIO-Fri prosj.st. med.,helse,biol

Defining the role of Axl in normal and malignant mammary stem cells

Metastasis accounts for >90% of cancer-related mortality. Malignant cells carry oncogenic mutations that engender uncontrolled growth and epigenetic activation of stem cell features, chemotherapeutic resistance, immune modulation and metastasis. Tumor cel l epithelial-to-mesenchymal transition (E...

Tildelt: kr 4,8 mill.

Prosjektperiode: 2011-2015

Sted: Vestland

FORNY-3-Kommersialisering av FoUresultater

Kommersialiseringsstipend: "An innovative drug target validation and discovery technology"

...

Tildelt: kr 1,0 mill.

Prosjektperiode: 2008-2009

Sted: Vestland

FUGE-Funksjonell genomforskn.i Norg

Contextual Regulation of Cell Proliferation & Differentiation in Angiogenesis: Integrated Functional Genomic Discovery &Validation Approach

Angiogenesis, the formation of new blood vessels from extant vasculature, is a fundamental homeostatic process and a key factor in the progression of many pathological conditions. Angiogenesis is defined by the growth and differentiation of endothelial ce lls. We conceptualize angiogenesis as a c...

Tildelt: kr 5,3 mill.

Prosjektperiode: 2007-2011

Sted: Vestland

NANOMAT-Nanoteknologi og nye materialer

Nanostructured biomaterials for improved vascularization in tissue engineering

Understanding the interactions between cells and materials is of fundamental importance for tissue engineering and regenerative medicine. An ideal scaffold should mimic the natural tissue microenvironment, directing cells to organize into a functional mul ticellular architecture by presenting the...

Tildelt: kr 6,2 mill.

Prosjektperiode: 2007-2010

Sted: Vestland

FORNY-3-Kommersialisering av FoUresultater

A Novel Approach to Pharmaceutical Target Validation: A Commercialization Opportunity

...

Tildelt: kr 1,5 mill.

Prosjektperiode: 2007-2008

Sted: Vestland

FUGE-Funksjonell genomforskn.i Norg

Improved Tumor Models by Functional Genomic Tissue Engineering

Cancer is not a single cell disease: tumors comprise two distinct but interdependent compartments,neoplastic tumor cells and an interposed supporting stroma (e.g. connective tissue, blood vessels). All tumors require stroma for nutritional support and was te product removal and a strong correlati...

Tildelt: kr 2,2 mill.

Prosjektperiode: 2006-2008

Sted: Vestland